Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936221 · ClinicalTrials.gov registry record · Phase 2
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
NCT00936221 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 385 participants.
The verdict
NCT00936221, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
Study Summary
To assess the efficacy in terms of overall survival of AZD6244 in combination with dacarbazine, compared with dacarbazine alone, in first line patients with BRAF mutation positive advanced cutaneous or unknown primary melanoma
Interventions
- DRUG Placebo
- DRUG Dacarbazine
- DRUG AZD6244
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2009-07 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00936221
The ClinicalTrials.gov registry entry for NCT00936221 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00936221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00936221 about?
NCT00936221 is a clinical study titled "Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients". To assess the efficacy in terms of overall survival of AZD6244 in combination with dacarbazine, compared with dacarbazine alone, in first line patients with BRAF mutation positive advanced cutaneous or unknown primary melanoma
What is the current status of trial NCT00936221?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2009-07. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00936221?
The interventions under investigation include: Placebo (DRUG), Dacarbazine (DRUG), AZD6244 (DRUG).
Who is sponsoring clinical trial NCT00936221?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.